伊立替康联合卡培他滨在晚期直肠癌的临床疗效观察  

Clinical observation of irinotecan combined capecitabine in treatment of advanced rectal cancer

作　　者：孟宪禄[1] 樊青霞[1] 王春燕[2] 

机构地区：[1]郑州大学第一附属医院,郑州450052 [2]渑池县人民医院

出　　处：《医药论坛杂志》2013年第5期52-53,56,共3页Journal of Medical Forum

摘　　要：目的探讨伊立替康(CPT-11)联合卡培他滨(Capecitabine,希罗达)治疗晚期直肠癌的客观疗效及毒性反应。方法回顾性分析21例经病理证实均为晚期直肠癌患者的临床资料。具体用法:伊立替康70 mg/m2,静脉注射30min,第1、8d;卡培他滨1000 mg/m2,口服,2次/d,第1～14d。21d为1周期,化疗两个或两个周期以上评价疗效及其毒性反应。结果 21例患者均可评价疗效,全组CR4例,PR9例,SD 5例,PD 3例,有效率(RR)为61.90%(13/21);肿瘤中位进展时间为8.2个月。毒性反应主要为骨髓抑制、脱发及疲乏。结论伊立替康联合卡培他滨治疗晚期直肠癌有相对较好疗效,不良反应可以耐受,用药安全,值得临床进一步推广。Objective To evaluate the efficacy and toxicity of advanced rectal cancer treated with irinotecan combined eapeeitabine. Methods Totally 21 patients with locally advanced rectal cancer were retrospectively analyzed. Advanced rectal cancer basede chemotherapy received irinotecan 70mg/m2 on day 1 and eapecitabine（ 1000mg/m2 po bid）on day I to 14,the regimen was repeated every 3 week and efficacy and toxicity were evaluated after two cycles. Results In 21 evalu- able patients ,4 cases had completed response ,9 eases had parti＇,d response ,5 cases had stable disease and 3 cases with pro- gressive disease. The response rate of the whole group was 61.90%. Median time to progression was 8. 2 months. The main toxicities were myelosuppression ,hairloss and fatigue. Conclusions The regimen irinotecan combined eapecitabine for ad- vanced rectal cancer show more effectiveness and all adverse reactions are tolerable, which is worthy of further clinical re- search.

关 键 词：晚期直肠癌 伊立替康 卡培他滨 化学治疗 

分 类 号：R735.37[医药卫生—肿瘤]